Clinical trials: Post COVID-19 Patients
Postural Orthostatic Tachycardia Syndrome
Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS
The study aims to investigate the safety, tolerability, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod compared to placebo in participants with post-COVID-19 postural orthostatic…
- Trial name
- POTS (NCT05633407)
- Testing
- Efgartigimod
- Where
- 11 sites in United States
- Volunteers
- 53 people
- Sponsor
- argenx
Depression, COVID-19
Effectiveness and Tolerability of аgomelatine in the Treatment of Patients With Depression After SARS-CoV-2 (TELESPHOR)
This is a multi-centre, observational, non-interventional study, which will prospectively collect clinical and socio-demographic data from patients with depression occurred after COVID 19 in real clinical settings during 8 weeks…
- Trial name
- TELESPHOR (NCT05323994)
- Where
- Russia
- Volunteers
- 104 people
- Sponsor
- Servier Russia
Cognitive Impairment, Long COVID
Addressing Cognitive Fog in Long-COVID-19 Patients
This study will assess two options to help patients better manage the cognitive fog and emotional distress that may be associated with having Long-COVID.
- Trial name
- NCT05597722
- Testing
- Digital cognitive behavioral intervention-RxWell, Amphetamine-Dextroamphetamine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Eva Szigethy
Breast Cancer Related Lymphedema, Covid19
Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment
This study aims to elicit patient experiences, choices, and side effects associated with the COVID-19 vaccine after breast cancer surgery.
- Trial name
- LymphVAX (NCT04872738)
- Testing
- Survey
- Where
- United States
- Volunteers
- 714 people
- Sponsor
- Massachusetts General Hospital
Post COVID-19 Condition, Long COVID
Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
The purpose of this study is to assess the efficacy and safety of Ampligen® administered twice weekly by intravenous (IV) infusions in subjects experiencing the Post-COVID Condition of fatigue.
- Trial name
- NCT05592418
- Testing
- Rintatolimod
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- AIM ImmunoTech Inc.